☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
App
Advertisement
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Samsung Bioepis
Samsung Bioepis Receives EC’s Marketing Authorization for Epysqli (biosimilar, eculizumab) to Treat Paroxysmal Nocturnal Hemoglobi...
May 31, 2023
Samsung Bioepis Reports P-III Trial Results of SB3 (biosimilar, trastuzumab) for HER2-Positive Breast Cancer
May 8, 2023
Samsung Bioepis Presents 52 Weeks P-III Study Results of SB15, Proposed biosimilar to Eylea (aflibercept) for Neovascular Age-Rela...
April 25, 2023
Samsung Bioepis Reports P-III Study Results of SB11 (biosimilar, ranibizumab) for Neovascular Age-Related Macular Degeneration
April 22, 2023
PharmaShots' Key Highlights of First Quarter 2023
April 3, 2023
Samsung Bioepis Reports P-I Study Results of SB17, a Proposed Biosimilar to Stelara
March 17, 2023
Load more...
Back to Home